- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03021993
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Panoramica dello studio
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Newly diagnosed histologically proven locoregional OCSCC without evidence of distant metastases and a clinically determined T-stage of 2-4,
OR
Recurrent or persistent histologically proven locoregional OCSCC that was initially treated with surgery alone, and a clinically determined recurrent T-stage of 2-4.
Note - OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa.
Note - To allow sufficient tumor tissue for the immunological analyses, patients with T-stage 1 OCSCC will be excluded
- Greater than or equal to 18 years of age
- ECOG performance status of 0 or 1
Screening labs must meet the following criteria and must be obtained within 14 days prior to registration:
- WBC > 2,000/µL
- Absolute Neutrophil Count >1,500/µL
- Platelets > 100 X 103/µL
- Hemoglobin > 9.0 g/dL
- Serum creatinine < 1.5 X ULN or CrCl > 40mL/min (if using the Cockcroft-Gault formula below):
Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
- AST/ALT ≤ 3 x ULN
- Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- Reproductive Status:
WOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception with a failure rate of less than 1% per year for a period of 31 weeks after the last dose of investigational product.
WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45.
Women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to registration Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men, are not required to use contraception.
Exclusion Criteria:
- Prior immunotherapy or treatment with another anti PD 1 agent
- Prior chemotherapy including Cetuximab or radiation therapy
- Previous severe hypersensitivity reaction to another monoclonal antibody
- Women who are pregnant, lactating or expecting to conceive
- Men who are expecting to father children within the research period
- Known history of HIV or AIDS
- Positive test for HBV sAg or HCV antibody indicating acute or chronic infection
- Concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma
- Unresectable primary tumor or regional disease; presence of distant metastases.
- History of pneumonitis or interstitial lung disease
- Active, known or suspected autoimmune disease. Note: Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
- Presence of condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Nivolumab
Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
|
Nivolumab will be administered on days 1, 15 and 29.
If disease has progressed at day 29, the subject will proceed to surgery.
If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Objective response rate using pathological response
Lasso di tempo: Time of surgery (day 36 or day 50)
|
Objective response rate: the sum of patients with either a pCR defined as no invasive and no in situ residuals present in the surgical specimen or partial pathologic response defined at least a 30% reduction in the size of the lesion in the surgical specimen.
The reduction in size will be determined by comparing the pretreatment clinical measurements (the sum of the greatest axial measurement obtained with calipers at the time of initial evaluation) with the final pathologic measurements.
|
Time of surgery (day 36 or day 50)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Level of Treg cells in peripheral blood using immunostaining
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
1. Levels of Treg cells in pre and post treatment peripheral blood will be evaluated using immunostaining for CD4 and flow cytometric analysis of Foxp3.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Level of activated T-cells in peripheral blood
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
2. Levels of activated T-cells in peripheral blood will be assessed using flow cytometry for expression of CD69, IFN γ, T-bet and ICOS in CD4+ cells.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Level of immune stimulatory cytokines in peripheral blood
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
3. Intratumoral immune activity assessed by levels of immune stimulatory cytokines including IL-2, IFN γ, and IL-12 or inhibitory cytokine, IL10 and TGF-beta, in OCSCC tumor lysates will be measured flow cytometrically by cytokine bead array.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of Th1 responses in CD4+ cells from peripheral blood
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
Expression of IL-2 (Th1 responses) in CD4+ cells from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of Th2 responses in CD4+ cells from peripheral blood
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
Expression of IIL 10 (Th2 responses) in CD4+ cells from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of CD8+ cells expressing granzyme B (ctolytic response) from peripheral blood
Lasso di tempo: Day 1 and time of surgery (day 36 or day 50)
|
2. Expression of CD8+ cells expressing granzyme B (cytolytic response) from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: David Neskey, MD, Medical University of South Carolina
Pubblicazioni e link utili
Pubblicazioni generali
- Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19;2(10):100426. doi: 10.1016/j.xcrm.2021.100426. eCollection 2021 Oct 19.
- Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19;2(10):100411. doi: 10.1016/j.xcrm.2021.100411. eCollection 2021 Oct 19.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 102510
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Oral Cavity SCC
-
International Agency for Research on CancerUniversity of Cambridge; Kilimanjaro Clinical Research InstituteCompletato
-
University of California, DavisCompletatoPreoccupazioni cognitive soggettive (SCC)Stati Uniti
-
SirnaomicsCompletato
-
Tufts Medical CenterDUSA Pharmaceuticals, Inc.CompletatoCheilite attinica | Carcinoma a cellule squamose in situ (SCC-is) | Carcinoma a cellule squamose (SCC) | Terapia fotodinamica (PDT) | Chirurgia MohsStati Uniti
-
Novartis PharmaceuticalsAttivo, non reclutanteEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaTaiwan, Stati Uniti, Olanda, Spagna, Corea, Repubblica di, Italia, Giappone, Canada, Singapore
-
InflaRx GmbHMerck Sharp & Dohme LLCTerminatoSCC - Carcinoma a cellule squamose della pelleStati Uniti, Spagna, Germania, Belgio, Francia
-
Institut de Cancérologie de LorraineNon ancora reclutamentoSCC - Carcinoma a cellule squamose | Neoplasie del tratto aerodigestivo superiore (UADT).Francia
-
Rigshospitalet, DenmarkCompletatoCancro orale | Lingua SCCDanimarca
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...RitiratoCarcinoma a cellule basali (BCC) | Carcinoma a cellule squamose (SCC)
Prove cliniche su Nivolumab
-
Universitair Ziekenhuis BrusselNon ancora reclutamento
-
Bristol-Myers SquibbReclutamentoMelanomaSpagna, Stati Uniti, Italia, Chile, Grecia, Argentina
-
Jason J. Luke, MDArray BioPharmaAttivo, non reclutanteMelanoma | Carcinoma a cellule renali | Tumore solido | Carcinoma polmonare non a piccole cellule | Carcinoma a cellule squamose della testa e del colloStati Uniti
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatoGlioblastoma ricorrenteStati Uniti
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminato
-
HUYABIO International, LLC.Bristol-Myers SquibbAttivo, non reclutanteMelanoma non resecabile o metastatico | Metastasi cerebrale progressivaNuova Zelanda, Spagna, Stati Uniti, Belgio, Francia, Giappone, Germania, Corea, Repubblica di, Singapore, Australia, Brasile, Sud Africa, Italia, Cechia, Austria, Porto Rico, Regno Unito
-
Bristol-Myers SquibbCompletatoCancro ai polmoniItalia, Stati Uniti, Francia, Federazione Russa, Spagna, Argentina, Belgio, Brasile, Canada, Chile, Cechia, Germania, Grecia, Ungheria, Messico, Olanda, Polonia, Romania, Svizzera, Tacchino, Regno Unito
-
Universitätsklinikum Hamburg-EppendorfCharite University, Berlin, Germany; University Hospital, Essen; Westpfalz-Clinical...Attivo, non reclutante
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkAttivo, non reclutanteCarcinoma a cellule renali avanzatoStati Uniti
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical University... e altri collaboratoriReclutamentoCarcinoma epatocellulare (HCC)Taiwan